摘要
随着免疫治疗2.0时代的到来,免疫检查点阻断剂(ICIs)已成为多种类型肿瘤治疗的新选择。多项研究表明,肿瘤患者肠道微生物与ICIs治疗反应密切相关,肠道微生物通过易位、免疫调节、代谢、酶促降解和多样性变异影响ICIs的疗效。此外,ICIs在改变肠道微生物组成和减少细菌多样性的同时,增加了胃肠道免疫相关不良反应。肠道微生物在预测ICIs疗效及免疫毒性方面有其独特的临床价值,故对应用ICIs的肿瘤患者进行肠道微生物分析已成为一种潜在需求。本综述主要介绍肠道微生物与ICIs相互作用机制的最新研究进展,以便更好地识别ICIs的应答者并提高其疗效和安全性。
With the advent of the era of immunotherapy 2.0,immune checkpoint inhibitors(ICIs)have become a new choice for the treatment of multiple types of tumors.A number of studies have shown that gut microbiomes of tumor patients are closely related to the response to ICIs treatment,and intestinal microorganisms affect the efficacy of ICIs through translocation,immune regulation,metabolism,enzymatic degradation and diversity variation.In addition,ICIs increase gastrointestinal immune-related adverse reactions while altering intestinal microbial composition and reducing bacterial diversity.Gut microorganism has its unique clinical value in predicting the efficacy and immunotoxicity of ICIs,so it has become a potential demand to analyze gut microorganism in patients using ICIs.This review mainly introduces the latest progression in the interaction mechanism between gut microbiomes and ICIs,so as to better identify ICIs responders and improve their efficacy and safety.
作者
陈星星
仓顺东
CHEN Xingxing;CANG Shundong(Department of Oncology,People's Hospital of Zhengzhou University,Zhengzhou 450003,China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2020年第4期374-377,共4页
Chinese Clinical Oncology
